Stock Events

Stock Events

BioAtla 

$1.3200
78
+$0.14+11.86% Friday 19:59

Statistics

Day High
2.1
Day Low
1.51
52W High
71.5
52W Low
1.07
Volume
1,031,528
Avg. Volume
78,803
Mkt Cap
2.2M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18NovExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-10
-6.74
-3.48
-0.22
Expected EPS
-7
Actual EPS
N/A

Financials

-2,980.35%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
2MRevenue
-59.61MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BCAB. It's not an investment recommendation.
Realty Income
12
O
NVIDIA
11
NVDA
Apple
10
AAPL
Microsoft
9
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals competes in the biotechnology space, focusing on innovative biologic medicines, similar to BioAtla's approach to developing antibody-based therapeutics.
AMGEN
AMGN
Mkt Cap233.78B
Amgen is a biotech firm that develops novel therapeutics, including in oncology, which is a direct competition to BioAtla's cancer-focused therapies.
Merck
MRK
Mkt Cap366B
Merck & Co. is a global healthcare company that develops cancer drugs and vaccines, competing with BioAtla's development of novel oncology treatments.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb is involved in discovering, developing, and delivering innovative medicines, including cancer therapies that compete with BioAtla's portfolio.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is a biopharmaceutical company that develops drugs for life-threatening illnesses, including cancer, making it a competitor to BioAtla.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a global pharmaceutical corporation with a broad range of healthcare products, including oncology, directly competing with BioAtla.
Novartis
NVS
Mkt Cap292.35B
Novartis is a healthcare company that focuses on innovative medicines, with a strong emphasis on oncology, competing with BioAtla's cancer therapies.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG is a leader in research-focused healthcare with a strong portfolio in cancer treatment, making it a competitor to BioAtla.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca is a global, science-led biopharmaceutical business that focuses on oncology, among other areas, competing with BioAtla.

About

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.
Show more...
CEO
Jay Short
Employees
41
Country
United States
ISIN
US09077B2034

Listings

OTC Link
US
BCAB
BOATS
BOATS
BCAB.BOATS

0 Comments

Share your thoughts

FAQ

What is BioAtla stock price today?▼
The current price of BCAB is $1.32 USD — it has increased by +11.86% in the past 24 hours. Watch BioAtla stock price performance more closely on the chart.
What is BioAtla stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange BioAtla stocks are traded under the ticker BCAB.
Is BioAtla stock price growing?▼
BCAB stock has fallen by -23.92% compared to the previous week, the month change is a -60.3% fall, over the last year BioAtla has showed a -95.08% decrease.
What is BioAtla market cap?▼
Today BioAtla has the market capitalization of 2.2M
When is the next BioAtla earnings date?▼
BioAtla is going to release the next earnings report on November 18, 2026.
What is BioAtla revenue for the last year?▼
BioAtla revenue for the last year amounts to 2M USD.
What is BioAtla net income for the last year?▼
BCAB net income for the last year is -59.61M USD.
How many employees does BioAtla have?▼
As of September 05, 2026, the company has 41 employees.
In which sector is BioAtla located?▼
BioAtla operates in the Health & Wellness sector.
When did BioAtla complete a stock split?▼
The last stock split for BioAtla was on April 06, 2026 with a ratio of 1:50.
Where is BioAtla headquartered?▼
BioAtla is headquartered in SAN DIEGO, United States.